Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Explore the latest advancements in gastrointestinal cancers care, wherever you are.
Browse the high quality scientific and educational content from the ESMO Gynaecological Cancers Congress 2024
A new version prepared by F. Lordick and E. Smyth
Andrés Cervantes, ESMO President, is pleased to announce the name of the ESMO President 2027-2028. Thank you to all who voted.
Join us from 6 to 8 December in Singapore to learn about the latest research findings, clinical trials, and treatment strategies in multidisciplinary oncology, with a focus on the Asia-Pacific region.
Contribute to recent developments on immune modulation, including tumour microenvironment, immunometabolism, epigenetics or microbiome
An encouraging first-in-class, first-in-human phase I study shows promising efficacy with durable responses in patients with advanced solid tumours
Online application is now open until 16 Jul 2024
Online application is now open!
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Edited by Christina Fotopoulou, Antonio González-Martín, Marcia Hall
Internationally renowned experts invite you to submit your abstract for MAP 2024. This exclusive global congress, taking place from 16 to 18 October 2024 in London, UK, is focused on precision oncology and translational research.
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression
However, studies highlight cost as an obstacle to widespread accessibility in some countries
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
In POSITIVE study, menstruation resumptions occurred mostly during the first 6 months, with young age being the most determinant factor
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Evidence for efficacy is based on the results from the IMerge study
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
Findings from the CONTINUUM study
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
In POSITIVE study, menstruation resumptions occurred mostly during the first 6 months, with young age being the most determinant factor
Evidence for efficacy is based on the results from the IMerge study
Findings from the CONTINUUM study
It is intended for the first-line treatment of patients with metastatic non-oncogene addicted NSCLC in combination with platinum-based chemotherapy
Findings from the MOTION study
Findings from the HARMONi-A study
It is the first FDA approval of a targeted therapy for paediatric patients with RET alterations
Findings from the ASC4FIRST study
New indication concerns combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024
The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract
The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours
Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Germany
Switzerland
Germany
Switzerland
Spain
Portugal
Portugal
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
